We serve Chemical Name:2-(2,5-dioxo-4,4-dipropylimidazolidin-1-yl)acetic acid CAS:723-09-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(2,5-dioxo-4,4-dipropylimidazolidin-1-yl)acetic acid
CAS.NO:723-09-1
Synonyms:5,5-Dipropyl-hydantoin-3-essigsaeure;(2,5-dioxo-4,4-dipropylimidazolidin-1-yl)acetic acid
Molecular Formula:C11H18N2O4
Molecular Weight:242.27200
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.167g/cm3
Index of Refraction:1.487
PSA:90.20000
Exact Mass:242.12700
LogP:0.53970
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5,5-Dipropyl-hydantoin-3-essigsaeure chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2,5-dioxo-4,4-dipropylimidazolidin-1-yl)acetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2,5-dioxo-4,4-dipropylimidazolidin-1-yl)acetic acid Use and application,(2,5-dioxo-4,4-dipropylimidazolidin-1-yl)acetic acid technical grade,usp/ep/jp grade.
Related News: TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, 5-Hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 6 -O-(6-deoxyhexopyranosyl)hexopyranoside manufacturers UQUIFA is a manufacturer of APIs and intermediates for the pharmaceutical industry globally. The company has 3 manufacturing sites (2 in Spain and 1 in Mexico) with strict adherence to all regulatory norms. 2-(6-methyl-1-benzofuran-3-yl)acetate suppliers While Stevanato has been in the headlines for its involvement in the fight against Covid-19—its factories immediately sprang to work producing vials and syringes for vaccines when Italy was still under lockdown in April 2020—vaccines only made up 4% of the company’s revenues in 2020 and 2019. Tricosanyl stearate vendor & factory.
